Evidence map›Paper›PMID 38793063›Full record

ArticleJournal of personalized medicine2024

Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.

Robert J Seager, Heidi Ko, Sarabjot Pabla, Maria-Fernanda Senosain, Pawel Kalinski, Erik Van Roey, Shuang Gao, Kyle C Strickland, Rebecca Ann Previs, Mary K Nesline and 9 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Robert J SeagerLabcorp Oncology, Buffalo, NY 14263, USA.
Heidi KoLabcorp Oncology, Durham, NC 27710, USA.
Sarabjot PablaLabcorp Oncology, Buffalo, NY 14263, USA.
Maria-Fernanda SenosainLabcorp Oncology, Buffalo, NY 14263, USA.
Pawel KalinskiRoswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0001-7025-3562
Erik Van RoeyLabcorp Oncology, Buffalo, NY 14263, USA.
Shuang GaoLabcorp Oncology, Buffalo, NY 14263, USA.
Kyle C StricklandLabcorp Oncology, Durham, NC 27710, USA.
Rebecca Ann PrevisLabcorp Oncology, Durham, NC 27710, USA.
Mary K NeslineLabcorp Oncology, Durham, NC 27710, USA.
Stephanie HastingsLabcorp Oncology, Durham, NC 27710, USA.
Shengle ZhangLabcorp Oncology, Buffalo, NY 14263, USA.
Jeffrey M ConroyLabcorp Oncology, Buffalo, NY 14263, USA.
Taylor J JensenLabcorp Oncology, Durham, NC 27710, USA.
Marcia EisenbergLabcorp, Burlington, NC 27710, USA.
Brian CaveneyLabcorp, Burlington, NC 27710, USA.
Eric A SeversonLabcorp Oncology, Durham, NC 27710, USA.
Shakti RamkissoonLabcorp Oncology, Durham, NC 27710, USA.
Shipra GandhiRoswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0003-3506-0284

Funding

Identifying the role of interferon and interferon-regulated chemokines in stress-induced immunosuppression in triple negative breast cancerR03TR004607 · NCATS · ROSWELL PARK CANCER INSTITUTE CORP · PI GANDHI, SHIPRA · 2023 to 2023
$174k
NCATS NIH HHS R03 TR004607Roswell Park Comprehensive Cancer Center Institutional funds
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast cancerchemotherapycombination therapygene expression profilingimmune checkpoint inhibitorsimmune profilingimmunotherapyneoadjuvanttriple-negativetumor microenvironment

Identifiers

PMID38793063
PMCPMC11122407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.